Nektar Therapeutics (NKTR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Nektar Therapeutics (NKTR) closed at USD 36.89 on 2026-10-14, a change of -39.4 % over the past year, with a market capitalization of USD 1.29B.

Nektar Therapeutics recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Nektar Therapeutics key figures

Previous close

USD 36.89 (2026-10-14)

1-year change

-39.4 %

Market cap

USD 1.29B

Enterprise value

USD 739.47M

P/E ratio (trailing)

-1.99

P/E ratio (forward)

-3.66

EPS (trailing)

-18.96

EPS (forward)

-10.30

PEG ratio

0.31

Price to book

1.43

Revenue growth

-9.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.30

Employees

63

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Nektar Therapeutics and compare it with other stocks.